Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Head-to-head clinical trial toevaluate the combination of Actimab-A with KEYTRUDA versus KEYTRUDA alone for with PD-L1 expression and locally advanced metastatic head and neck squamous cell carcinoma

Next Previous
Search
Trial Profile

Head-to-head clinical trial toevaluate the combination of Actimab-A with KEYTRUDA versus KEYTRUDA alone for with PD-L1 expression and locally advanced metastatic head and neck squamous cell carcinoma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

    • Most Recent Events

    • 24 Mar 2025 New trial record
    • 18 Mar 2025 According to Actinium Pharmaceuticals media release, this study is a part of clinical trial program in solid tumors combining actimab-A with PD-1 checkpoint Inhibitor. The company expects to present initial proof of concept clinical data from the first of these trials in the second half of 2025 as well as provide an update on the outlook for the rest of the trials in the Actimab-A solid tumor program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top